Association between urine 6-sulfatoxy-melatonin level and intravesical Bacillus Calmette-Guerin treatment-induced sleep quality deterioration in patients with non-muscle invasive bladder cancer.
Bacillus Calmette-Guerin
Lower urinary tract symptoms
Melatonin
Patient reported outcome measures
Sleep
Urinary bladder neoplasms
Journal
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
received:
11
02
2022
accepted:
05
04
2022
pubmed:
16
4
2022
medline:
31
5
2022
entrez:
15
4
2022
Statut:
ppublish
Résumé
The level of 6-sulfatoxy-melatonin (SaMT), a metabolite of melatonin, in first-void morning urine reflects blood melatonin levels from the previous night. We investigated the association between urine SaMT and sleep quality deterioration in patients with non-muscle invasive bladder cancer (NMIBC) treated with intravesical Bacillus Calmette-Guerin induction therapy (iBCG). We enrolled 51 patients who received iBCG once weekly for 6 or 8 weeks. Patient-reported outcomes were assessed with questionnaires including the International Prostate Symptom Score (IPSS) and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (QLQC30). Questionnaires were completed before (baseline), during, at completion, and 1 and 3 months after iBCG. Melatonin and SaMT levels at baseline were measured in serum and first-void morning urine samples, respectively. Based on changes in the QLQC30 insomnia subscale, 28 (55%) patients experienced sleep quality deterioration (deterioration group). Urine SaMT values in the deterioration group were lower than those in the non-deterioration group (P = 0.0015; 7.5 vs 15.4 ng/mg creatinine, respectively). Nocturia scores in the non-deterioration group decreased over time, while those of the deterioration group remained high after completion of iBCG. A binary logistic regression analysis revealed that low urine SaMT levels (≤ 9.6 ng/mg creatinine), high IPSS nocturia scores at baseline, and high IPSS storage subscores at baseline were associated with BCG-induced sleep quality deterioration. This study confirmed the association among urine SaMT levels, nocturia, and sleep disturbance in patients with NMIBC who receive iBCG. We should be aware of treatment-induced impairments to aid in appropriate decision-making.
Identifiants
pubmed: 35426045
doi: 10.1007/s00520-022-07043-0
pii: 10.1007/s00520-022-07043-0
doi:
Substances chimiques
BCG Vaccine
0
Creatinine
AYI8EX34EU
Melatonin
JL5DK93RCL
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6145-6153Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249
doi: 10.3322/caac.21660
Babjuk M, Burger M, Capoun O, Cohen D, Compérat EM, Dominguez Escrig JL et al (2022) European Association of Urology Guidelines on non-muscle-invasive bladder cancer (Ta, T1, and Carcinoma in Situ). Eur Urol 81:75–94
doi: 10.1016/j.eururo.2021.08.010
Matsumoto H, Shiraishi K, Azuma H, Inoue K, Uemura H, Eto M et al (2020) Clinical Practice Guidelines for Bladder Cancer 2019 edition by the Japanese Urological Association: revision working position paper. Int J Urol 27:362–368
Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK et al (2020) Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 18:329–354
doi: 10.6004/jnccn.2020.0011
Blazeby JM, Hall E, Aaronson NK, Lloyd L, Waters R, Kelly JD et al (2014) Validation and reliability testing of the EORTC QLQ-NMIBC24 questionnaire module to assess patient-reported outcomes in non-muscle-invasive bladder cancer. Eur Urol 66:1148–1156
doi: 10.1016/j.eururo.2014.02.034
Gontero P, Oderda M, Mehnert A, Gurioli A, Marson F, Lucca I et al (2013) The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guerin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial. J Urol 190:857–862
doi: 10.1016/j.juro.2013.03.097
Siracusano S, Silvestri T, Bassi S, Porcaro AB, Cerruto MA, Talamini R et al (2018) Health-related quality of life after BCG or MMC induction for non-muscle invasive bladder cancer. Can J Urol 25:9480–9485
pubmed: 30281005
Miyake M, Nishimura N, Oda Y, Owari T, Hori S, Morizawa Y et al (2022) Intravesical Bacillus Calmette-Guerin treatment-induced sleep quality deterioration in patients with non-muscle invasive bladder cancer: functional outcome assessment based on a questionnaire survey and actigraphy. Support Care Cancer 30:887–895
doi: 10.1007/s00520-021-06468-3
Pesonen JS, Cartwright R, Vernooij RWM, Aoki Y, Agarwal A, Mangera A et al (2020) The impact of nocturia on mortality: a systematic review and meta-analysis. J Urol 203:486–495
doi: 10.1097/JU.0000000000000463
Arendt J (1998) Melatonin and the pineal gland: influence on mammalian seasonal and circadian physiology. Rev Reprod 3:13–22
doi: 10.1530/ror.0.0030013
Srinivasan V, Spence DW, Pandi-Perumal SR, Trakht I, Cardinali DP (2008) Therapeutic actions of melatonin in cancer: possible mechanisms. Integr Cancer Ther 7:189–203
doi: 10.1177/1534735408322846
Mehrzadi MH, Hosseinzadeh A, Juybari KB, Mehrzadi S (2020) Melatonin and urological cancers: a new therapeutic approach. Cancer Cell Int 20:444
doi: 10.1186/s12935-020-01531-1
Chen YT, Yang CC, Shao PL, Huang CR, Yip HK (2019) Melatonin-mediated downregulation of ZNF746 suppresses bladder tumorigenesis mainly through inhibiting the AKT-MMP-9 signaling pathway. J Pineal Res 66:e12536
doi: 10.1111/jpi.12536
Liu S, Liang B, Jia H, Jiao Y, Pang Z, Huang Y (2017) Evaluation of cell death pathways initiated by antitumor drugs melatonin and valproic acid in bladder cancer cells. FEBS Open Bio 7:798–810
doi: 10.1002/2211-5463.12223
Cheng TC, Lee YH, Chang YP, Lee DC (2020) Improved urinary melatonin level as the perspective indicator that leads to better sleeping quality in bladder cancer patients. Ther Adv Urol 12:1756287220940870
doi: 10.1177/1756287220940870
Miyake M, Iida K, Nishimura N, Miyamoto T, Fujimoto K, Tomida R et al (2021) Non-maintenance intravesical Bacillus Calmette-Guérin induction therapy with eight doses in patients with high- or highest-risk non-muscle invasive bladder cancer: a retrospective non-randomized comparative study. BMC Cancer 21:266
doi: 10.1186/s12885-021-07966-7
Degboe A, Ivanescu C, Rohay JM, Turner RR, Cella D (2019) Validity and performance of the Functional Assessment of Cancer Therapy-Bladder (FACT-Bl) among advanced urothelial cancer patients. Support Care Cancer 27:4189–4198
doi: 10.1007/s00520-019-04709-0
Kobayashi K, Takeda F, Teramukai S, Gotoh I, Sakai H, Yoneda S et al (1998) A cross-validation of the European Organization for Research and Treatment of Cancer QLQ-C30 (EORTC QLQ-C30) for Japanese with lung cancer. Eur J Cancer 34:810–815
doi: 10.1016/S0959-8049(97)00395-X
Tokuda Y, Okubo T, Ohde S, Jacobs J, Takahashi O, Omata F et al (2009) Assessing items on the SF-8 Japanese version for health-related quality of life: a psychometric analysis based on the nominal categories model of item response theory. Value Health 12:568–573
doi: 10.1111/j.1524-4733.2008.00449.x
Schernhammer ES, Berrino F, Krogh V, Secreto G, Micheli A, Venturelli E et al (2008) Urinary 6-sulfatoxymelatonin levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 100:898–905
doi: 10.1093/jnci/djn171
Xu J, Huang L, Sun GP (2017) Urinary 6-sulfatoxymelatonin level and breast cancer risk: systematic review and meta-analysis. Sci Rep 7:5353
doi: 10.1038/s41598-017-05752-9
Pinheiro JC, Bates DM (2002) Mixed-Effects Models in S and S-PLUS. Springer, New York
Srinivasan V, Pandi-Perumal SR, Brzezinski A, Bhatnagar KP, Cardinali DP (2011) Melatonin, immune function and cancer. Recent Pat Endocr Metab Immune Drug Discov 5:109–123
doi: 10.2174/187221411799015408
Olesen T, Paul J, Gramme P, Drake MJ, Vandewalle J, Everaert K (2020) Assessment of the most impactful combination of factors associated with nocturia and to define nocturnal polyuria by multivariate modelling. J Clin Med 9:2262
doi: 10.3390/jcm9072262
Nowak R, McMillen IC, Redman J, Short RV (1987) The correlation between serum and salivary melatonin concentrations and urinary 6-hydroxymelatonin sulphate excretion rates: two non-invasive techniques for monitoring human circadian rhythmicity. Clin Endocrinol (Oxf) 27:445–452
doi: 10.1111/j.1365-2265.1987.tb01172.x
Rzepka-Migut B, Paprocka J (2020) Melatonin-measurement methods and the factors modifying the results. a systematic review of the literature. Int J Environ Res Public Health 17:1916
doi: 10.3390/ijerph17061916
Liu S, Madu CO, Lu Y (2018) The role of melatonin in cancer development. Oncomedicine 3:37–47
doi: 10.7150/oncm.25566
Alonso-Gonzalez C, Menendez-Menendez J, Gonzalez-Gonzalez A, Gonzalez A, Cos S, Martinez-Campa C (2018) Melatonin enhances the apoptotic effects and modulates the changes in gene expression induced by docetaxel in MCF7 human breast cancer cells. Int J Oncol 52:560–570
pubmed: 29207126
Pandi-Perumal SR, Sirinivasan V, Maestroni GJ, Cardinali DP, Poeggeler B, Hardeland R (2006) Melatonin: Nature’s most versatile biological signal? FEBS J 273:2813–2838
doi: 10.1111/j.1742-4658.2006.05322.x